WANY
CRBU icon

Wealthspire Advisors (New York)’s Caribou Biosciences CRBU Stock Holding History

Wealthspire Advisors (New York)’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-7,500
Closed -$17.5K – 1424
2025
Q3 		$17.5K Buy
+7,500
New +$14.2K ﹤0.01% 1741

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Wealthspire Advisors (New York)'s CRBU Position: Q4 2025 in Review

Wealthspire Advisors (New York) sold out of Caribou Biosciences (CRBU) in Q4 2025, closing a stake of 7,500 shares — an estimated $17.5K sold.

Wealthspire Advisors (New York) first reported a position in CRBU in Q3 2025 and held it in 1 quarter. The position peaked at $17.5K in Q3 2025. 124 funds tracked by Wall St. Rank hold CRBU as of Q4 2025.

  • Wealthspire Advisors (New York) reported no remaining Caribou Biosciences position as of Q4 2025 after selling out during the quarter.
  • Wealthspire Advisors (New York) sold 7,500 Caribou Biosciences shares in Q4 2025, an estimated $17.5K.
  • Wealthspire Advisors (New York) first reported a position in Caribou Biosciences in Q3 2025 and held it in 1 quarter.
  • Wealthspire Advisors (New York)'s Caribou Biosciences position peaked at $17.5K in Q3 2025.
  • 124 funds tracked by Wall St. Rank held Caribou Biosciences as of Q4 2025.

Based on Wealthspire Advisors (New York)'s 13F filing for Q4 2025, filed 13 Feb 2026.